Navigation Links
Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
Date:6/1/2009

mpared the THEROS CancerTYPE ID cancer type predictions to the actual primary sites previously identified for each patient.

Among the 20 samples that were appropriate for testing, 15 site-of-origin predictions (75 percent) provided by the THEROS CancerTYPE ID test were accurate based on the actual clinical diagnoses. In contrast, traditional diagnostic methods often fail to properly diagnose unknown cancers even after extensive work-up that could cost up to $18,000.(2)

"Cancers of unknown primary origin present unique and significant challenges to both medical professionals and patients," said Richard Ding, bioTheransotics chief executive officer. "As the clinical validity and utility of molecular diagnostic tests such as the THEROS CancerTYPE ID continue to be demonstrated in clinical studies, we are eager to work with the oncology and pathology communities to integrate molecular diagnostic tools into routine cancer diagnosis."

The abstract, "Unknown Primary Cancer (UPC): Accuracy of Tissue of Origin Prediction by Molecular Profiling" is available online at the ASCO Web site, www.abstract.asco.org.

About bioTheranostics

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in genomic profiling and proprietary algorithms, bioTheranostics provides innovative tests to the oncology community that help drive personalized treatment. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: THEROS CancerTYPE ID(R), a molecular cancer classifier particularly helpful for patients diagnosed with primary or metastatic cancer where the origin is uncertain or unknown; and the THEROS Breast Cancer Index(SM), a combination of THEROS H/I(SM) (HOXB13:
'/>"/>

SOURCE bioTheranostics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Hovione today announced that its API plant in ... pre-approval inspection by the US Food and Drug Administration (FDA). ... Safety Officer, Ms. Britanny Terhar , lasted 5 days ... concluded on the 25 th . The inspection confirmed the ... Good Manufacturing Practices (GMP) and no Form 483 observations were ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... in New York results of AFF008, ... Parkinson,s disease. PD01A is the first therapy against the protein ... The Michael J. Fox Foundation for Parkinson,s Research ... and presented at the press conference on the impact a ...
(Date:7/31/2014)... 2014 Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics ... a conference call on Thursday, August 14, 2014, at 4:30 ... ended June 30, 2014. Financial results will be issued in ... Chairman, President and CEO James LaFrance will host ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern ...
Breaking Medicine Technology:Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... Life Technologies Corporation (NASDAQ: LIFE ) ... with GlaxoSmithKline Biologicals S.A. (GSK) to develop a diagnostic ... GSK candidate cancer immunotherapy. Specifically, Life will develop a ... candidate designed to identify patients likely to benefit from ...
... (Cayman) Inc. (NYSE: WX ), a leading ... operations in China and the United States, today announced ... quarter of 2011 after the New York Stock Exchange ... Friday morning, November 11, 2011 Shanghai time). The earnings ...
Cached Medicine Technology:Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 2Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 3Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 4WuXi PharmaTech Schedules Third-Quarter 2011 Earnings Release 2
(Date:7/31/2014)... 2014 United Theological Seminary is pleased ... Le Donne and Peter J. Bellini. Both began their ... United is a Director of Non-Degree Programs, Mark Abbott, ... Anthony Le Donne, Assistant Professor of New Testament, received ... New Testament, Second Temple Judaism, and Greek courses. His ...
(Date:7/31/2014)... Cosmetic Town is a new web directory ... considering cosmetic treatments. The site features doctors who ... to educate prospective patients on a variety of cosmetic ... referral system that helps patients find cosmetic specialists in ... fields. , Cosmetic Town started its recruitment of ...
(Date:7/31/2014)... The VitaSleep FDA cleared anti-snoring device ... an easier breathing capacity by slightly adjusting the position ... can breathe easier and helps reduce or even completely ... it can meet the needs of each individual snorer. ... by actual customer reviews. Johathan R. from Statham ...
(Date:7/31/2014)... Ce-Classes.com has developed a Learning Management ... to pass inspections and audits. Ce-Classes.com can ... accreditation and state licensing criteria by providing their ... administrators can monitor employee compliance with mandatory training ... can be developed based on the policies and ...
(Date:7/31/2014)... Andrie, Inc. V. Dept. of Treasury, Mich. S. ... has made the determination that a purchaser of tangible goods ... was unable to prove during an audit that sales ... Court of Appeals decision on whether a purchaser bears the ... purchases from Michigan sellers. The Court states “in order to ...
Breaking Medicine News(10 mins):Health News:Growing Seminary Welcomes New Faculty 2Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3
... always ideal for many with low risk disease, researchers ... patients with prostate cancer that has a low risk ... may be a suitable treatment option, according to a ... (or whether) to treat localized prostate cancer is controversial ...
... ... MD is now performing a new procedure at Baptist Medical Center in Jackson, Miss. ... referred to as a myomectomy, or fibroidectomy. , ... Jackson, MS (Vocus) June 18, 2010 -- Baptist Medical ...
... Poor kids in bilingual families need extra support, study ... children in poor families are at increased risk for ... summer holidays, according to the American Speech-Language-Hearing Association. , ... the summer, says the ASHA, which offers the following ...
... Rome, Italy, Friday 18 June 2010: There is significant ... terms of access to biological treatments for rheumatoid arthritis ... four continents presented today at EULAR 2010, the Annual ... Italy. Furthermore, findings from a separate study show that ...
... , ... In today’s back to school environment, many ... have seen on T.V. or the Internet to inquire about returning ... realize is that their work and military experience, training certificates, licenses ...
... consumption dropped, study found , FRIDAY, June 18 (HealthDay ... may reduce consumption and help lower levels of obesity ... suggests. , Researchers examined what happened during a time ... in Boston increased the price of regular soft drinks ...
Cached Medicine News:Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility 2Health News:Country economy is a stronger predictor of therapy initiation 2Health News:College Equalizer Takes College Counseling Beyond the Status Quo to Help Adult Learners Find the Best School 2Health News:College Equalizer Takes College Counseling Beyond the Status Quo to Help Adult Learners Find the Best School 3Health News:People May Skip Soft Drinks Rather Than Pay More 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: